Filing Flows › Corcept Therapeutics (CORT) › How it makes money
How Corcept Therapeutics (CORT) makes money
Corcept Therapeutics (CORT) made $340M of revenue in the third quarter 2026 (Q3 2026), +64% from a year earlier. Hypercortisolism Products brought in $249M (73%); Lifyorli brought in $91.4M (27%). Of every dollar of revenue, 34¢ was left as operating profit, 37¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Hypercortisolism Products | $249M | 73.2% | +19% | +20% |
| Lifyorli | $91.4M | 26.8% | +92% | — |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $340M | 100.0% |
| Operating profit | $115M | 33.7% |
| Net earnings | $127M | 37.2% |
| Operating cash flow | $143M | 42.0% |
| Free cash flow | $142M | 41.8% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $340M | +64% |
| Q2 2026 | $256M | +32% |
| Q1 2026 | $165M | +5% |
| Q4 2025 | $202M | +11% |
| Q3 2025 | $208M | +14% |
| Q2 2025 | $194M | +19% |
| Q1 2025 | $157M | +7% |
From Corcept Therapeutics' 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does Corcept Therapeutics make money?
Corcept Therapeutics (CORT) made $340M of revenue in the third quarter 2026 (Q3 2026), +64% from a year earlier. Hypercortisolism Products brought in $249M (73%); Lifyorli brought in $91.4M (27%). Of every dollar of revenue, 34¢ was left as operating profit, 37¢ was left as net earnings.
What is Corcept Therapeutics' biggest business?
Hypercortisolism Products: $249M in the third quarter 2026, 73% of revenue, +20% from a year earlier.
What is Corcept Therapeutics' profit margin?
Net earnings were $127M, 37.2% of revenue, in the third quarter 2026; the operating margin was 33.7%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.